Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies - Top-Institutions - MDSpire

Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies

  • By

  • Piyanoot Jitthiang

  • Rattanavit Phandthong

  • Ployploen Phikulsod

  • Siwanon Jirawatnotai

  • Narongsak Kiatikajornthada

  • Harit Suwanrusme

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Molecular Oncology
    • Precision Medicine

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Translational Research
    • Precision Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Molecular Diagnostics
    • Clinical Trials

  • #4

    National Cancer Institute (NCI) - Center for Cancer Research
    National Cancer Institute (NCI) - Center for Cancer Research

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Translational Oncology
    • Clinical Trials

  • #5

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Precision Oncology
    • Molecular Pathology
    • Clinical Research

Original Source(s)

Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies

  • by Piyanoot Jitthiang, Rattanavit Phandthong, Ployploen Phikulsod, Siwanon Jirawatnotai, Narongsak Kiatikajornthada, Harit Suwanrusme

  • April 30, 2026

Related Content

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?